Azenta (NASDAQ:AZTA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued on Monday, Benzinga reports. They presently have a $37.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 21.63% from the company’s current price.
Separately, Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 26th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $41.20.
View Our Latest Stock Analysis on AZTA
Azenta Trading Down 1.4%
Azenta (NASDAQ:AZTA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%. The firm had revenue of $161.18 million during the quarter, compared to analysts’ expectations of $149.31 million.
Institutional Trading of Azenta
Several institutional investors and hedge funds have recently added to or reduced their stakes in AZTA. Integrated Wealth Concepts LLC acquired a new position in shares of Azenta in the first quarter valued at approximately $435,000. Millennium Management LLC lifted its holdings in shares of Azenta by 214.8% during the first quarter. Millennium Management LLC now owns 340,580 shares of the company’s stock worth $11,798,000 after purchasing an additional 232,405 shares during the period. Empowered Funds LLC grew its position in Azenta by 10.5% in the 1st quarter. Empowered Funds LLC now owns 6,482 shares of the company’s stock valued at $225,000 after buying an additional 618 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Azenta by 17.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 201,337 shares of the company’s stock valued at $6,974,000 after buying an additional 30,492 shares during the period. Finally, Creative Planning acquired a new position in Azenta in the 2nd quarter valued at $270,000. 99.08% of the stock is owned by hedge funds and other institutional investors.
Azenta Company Profile
Azenta, Inc (NASDAQ: AZTA) is a life sciences company that provides solutions for the management, storage, and analysis of biological samples. Its customers include pharmaceutical and biotechnology companies, academic and government research institutions, clinical research organizations, and other organizations involved in drug discovery, clinical research, and genomic analysis.
The company offers automated sample-management systems, ultra-low-temperature and cryogenic storage equipment, laboratory automation, consumables, and software for tracking and managing biological specimens.
Read More
- Five stocks we like better than Azenta
- 3 European Banks That Could Win Big From ECB Rate Hikes
- SM Energy’s Civitas Merger Is Paying Off, But the Stock’s Run Raises the Bar
- Intel’s Price Hikes Could Put $120 Back in Play
- Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
